Bilaal.Raja
Company record

LLY  ELI LILLY & Co

Trailing twelve months to 2026-06-30, as filed 2026-08-05 and not restated since.
Healthcare

Scale

Market cap
$1,019.1bn
Revenue TTM
$79.7bn
Net income TTM
$26.7bn
Free cash flow
—
Composite score
—
Sector rank
#13

Valuation

P / E
38.2
EV / EBITDA
—
EV / sales
13.4
FCF yield
—
Yield vs 10-yr
-2.66pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
33.5%
EBITDA margin
—
ROE
78.8%
ROIC
—
Revenue growth
49.6%

Insider activity, last 90 days

Net open-market
$-15.96m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Financial Results The following table summarizes certain financial information: Revenue increased for the three and six months ended June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices. The increased volume and the lower realized prices during the three and six months ended June 30, 2026 were primarily driven by Mounjaro and Zepbound. Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses. …ELI LILLY & Co, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →